The U.S. Food and Drug Administration (FDA) revised the boxed warning on the label for Lecanemab (LEQEMBI) effective 2026-07-21. This significant update specifically details the risk of amyloid related imaging abnormalities (ARIA), which are characterized as ARIA with edema (ARIA-E). The revision emphasizes that monoclonal antibodies directed against aggregated forms of beta amyloid, including LEQEMBI, can cause these abnormalities.

Background

Lecanemab (LEQEMBI) is a therapeutic monoclonal antibody. The boxed warning, also known as a 'black box warning,' is the strongest warning that the FDA requires for prescription drugs, indicating serious or life-threatening risks. The latest revision, effective 2026-07-21, explicitly addresses Amyloid Related Imaging Abnormalities (ARIA). The warning clarifies that ARIA, specifically ARIA with edema (ARIA-E), are potential adverse events associated with this class of drugs. This update serves to provide more precise information regarding the nature and characterization of these imaging abnormalities, which are known to occur with monoclonal antibodies targeting aggregated beta amyloid.

What this means

The revised boxed warning for Lecanemab (LEQEMBI) carries important implications for clinical practice and patient safety. Healthcare providers are now provided with more explicit details regarding the risk of Amyloid Related Imaging Abnormalities (ARIA), including ARIA with edema (ARIA-E). This necessitates a heightened awareness among clinicians for monitoring patients for signs and symptoms of ARIA, and for appropriate management strategies. The update reinforces the need for thorough patient counseling, ensuring that individuals considering or undergoing treatment with LEQEMBI fully understand the potential for these imaging abnormalities. For patient advocates, this revision highlights the ongoing commitment to drug safety and the importance of informed decision-making in the context of treatment options.

Source

This information was sourced from the FDA, detailing a label revision for Lecanemab (LEQEMBI) effective 2026-07-21. The full details of the revised label, including the complete boxed warning text, are publicly available on dailymed.nlm.nih.gov, a service of the National Library of Medicine.